Gosse C, Atassi G, Letourneux Y, Ardouin P, Gouyette A, Fournier J P, Roger P
Pavillon de Recherche, Institut Gustave-Roussy, Villejuif, France.
Anticancer Res. 1988 Nov-Dec;8(6):1419-22.
L1210 leukemia was used to evaluate the antitumour activity in vivo of CY233 (NSC 609224) a new water-soluble nitrosoureido derivative of deoxysugar currently being studied in preclinical trials. The antitumour activity of CY233 is dose-dependent with the same large therapeutic index whatever the route of administration (I.P., I.V., per os). Thus starting from a single dose of 10 mg/kg (less than 25% of the LD50), 80% to 100% of mice survive at 120 days, whether the drug is being administered I.V., I.P. or P.O. These results clearly emphasize the very original and promising potentiality of CY233 among the series of alkylating agents, and more precisely nitrosoureas.
L1210白血病被用于评估CY233（NSC 609224）的体内抗肿瘤活性。CY233是一种新的水溶性脱氧糖亚硝基脲衍生物，目前正处于临床前试验阶段。无论给药途径（腹腔注射、静脉注射、口服）如何，CY233的抗肿瘤活性均呈剂量依赖性，且具有相同的大治疗指数。因此，从单剂量10mg/kg（低于LD50的25%）开始，无论药物是通过静脉注射、腹腔注射还是口服给药，80%至100%的小鼠在120天时存活。这些结果清楚地强调了CY233在一系列烷化剂，更确切地说是亚硝基脲类药物中具有非常独特且有前景的潜力。
